Joint with: Neuroinflammation in Health and Disease
Neurodegeneration: From Neurocentric to System-Wide Perspectives
Jun 22–25, 2026 | Fairmont Chateau Whistler, Whistler, BC, Canada
Scientific Organizers:
Julia TCW, Christian Haass and Emma Mead
Jun 22–25, 2026 | Fairmont Chateau Whistler, Whistler, BC, Canada
Scientific Organizers:
Julia TCW, Christian Haass and Emma Mead
Available Formats:
Supported by the Directors' Fund
In Person
On Demand
Available Formats: = In Person = On Demand
Monday, June 22, 2026
Fundraising
Booking Function
Merchandise Options
Registration Options
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Tuesday, June 23, 2026
Breakfast
7:00–8:00 AM
Welcome and Keynote Session (Joint)
8:00–9:00 AM
Christian Haass, Ludwig-Maximilians University Munich
Modulation of Microglial Function
Modulation of Microglial Function
Astrid Iversen, University of Oxford
Genomic Risk for Neuroinflammation
Genomic Risk for Neuroinflammation
Integrating Degeneration and Inflammation (Joint)
9:00–11:15 AM
Malu G. Tansey, University of Florida
Role of Central-Peripheral Neuroimmune Cross-Talk in Neurodegeneration
Role of Central-Peripheral Neuroimmune Cross-Talk in Neurodegeneration
Bart De Strooper, University College London
Key Inflection Points in Alzheimer’s Disease Pathogenesis
Key Inflection Points in Alzheimer’s Disease Pathogenesis
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
Poster Setup
11:15–1:00 PM
On Own for Lunch
11:15–5:00 PM
Poster Viewing
1:00–10:00 PM
Panel Discussion: From Research to Clinical Practice
2:30–4:30 PM
Coffee Available
4:30–5:00 PM
Neurodegenerative Disease Diagnostic to Therapeutics
5:00–7:00 PM
Rahul Atmaramani †, insitro
Machine Learning to Identify Disease Relevant Phenotypes in ALS iPSC Cultures
Machine Learning to Identify Disease Relevant Phenotypes in ALS iPSC Cultures
Henne Holstege, Amsterdam UMC
Biomarker for Centenarians
Biomarker for Centenarians
Matthias Brendel, LMU Munich
Molecular Imaging with PET for Translation towards Therapeutics
Molecular Imaging with PET for Translation towards Therapeutics
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Wednesday, June 24, 2026
Breakfast
7:00–8:00 AM
Disease Overarching Mechanisms of Neurodegenerative Diseases
8:00–11:00 AM
Julia TCW, Boston University
Lipophagic Defect by APOE4 in AD Glia
Lipophagic Defect by APOE4 in AD Glia
Justin Ichida, USC Keck School of Medicine
Using Patient Stem Cells to Identify Therapeutic Targets for Familial and Sporadic ALS
Using Patient Stem Cells to Identify Therapeutic Targets for Familial and Sporadic ALS
Aaron D. Gitler, Stanford University School of Medicine
Single Cell Mechanisms of Neurodegeneration
Single Cell Mechanisms of Neurodegeneration
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Poster Setup
11:00–1:00 PM
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Career Roundtable
3:00–4:30 PM
Coffee Available
4:30–5:00 PM
Myeloid-Based Disease Mechanisms for Neurodegenerative Diseases
5:00–7:00 PM
Donna M. Wilcock, Indiana University School of Medicine
Therapeutic Trem2 Activation Ameliorates Amyloid-beta Deposition and Improves Cognition in the 5XFAD Model of Amyloid Deposition
Therapeutic Trem2 Activation Ameliorates Amyloid-beta Deposition and Improves Cognition in the 5XFAD Model of Amyloid Deposition
Zhiqiang An, The University of Texas Health Science Center at Houston
Antibodies Targeting the LILRB2/TREM2 Axis in AD
Antibodies Targeting the LILRB2/TREM2 Axis in AD
Marco Colonna, Washington University School of Medicine
Microglial Neurodegeneration Mechanisms
Microglial Neurodegeneration Mechanisms
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Thursday, June 25, 2026
Breakfast
7:00–8:00 AM
Drug Delivery (Joint)
8:00–11:00 AM
Fiona C. Elwood, Janssen R&D
Developing Drugs for CNS Disorders: Considerations for Therapies That Cross the BBB
Developing Drugs for CNS Disorders: Considerations for Therapies That Cross the BBB
Kate Monroe, Denali Therapeutics
Human Genetics Identifies Novel Microglial Targeting Therapeutic Approaches for Alzheimer's Disease
Human Genetics Identifies Novel Microglial Targeting Therapeutic Approaches for Alzheimer's Disease
Sebastian Boland, Prevail Therapeutics, Eli Lilly
Talk Title to be Announced
Talk Title to be Announced
Christopher J. Barnum, INmune Bio Inc.
Selective Targeting of Soluble TNF to Mitigate Neuroinflammation in Neurodegenerative Diseases
Selective Targeting of Soluble TNF to Mitigate Neuroinflammation in Neurodegenerative Diseases
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
On Own for Lunch
11:00–5:00 PM
Symposia Spotlight: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Target-Based Therapeutics
5:00–6:45 PM
Emma Mead, Oxford Drug Discovery Institute
USP11 Inhibitors and tau Proteostasis
USP11 Inhibitors and tau Proteostasis
Haiyan Peng, Alnylam Pharmaceuticals
The Application of RNAi Therapeutics in Neurodegenerative Diseases
The Application of RNAi Therapeutics in Neurodegenerative Diseases
Marcos Costa, F. Hoffmann-La Roche Ltd
Correcting RNA Mis-Splicing in TDP-43 Proteinopathy
Correcting RNA Mis-Splicing in TDP-43 Proteinopathy
Short Talk(s) Chosen from Abstracts
Closing Keynote Address
6:45–7:30 PM
Dennis J. Selkoe, Harvard Medical School
A Century of Alzheimer’s Research – Did We Finally Reach Our Goal?
A Century of Alzheimer’s Research – Did We Finally Reach Our Goal?
Meeting Wrap-Up: Outcomes and Future Directions
7:30–7:45 PM
Social Hour with Lite Bites
7:45–8:45 PM
Entertainment
8:00–11:00 PM
Cash Bar
8:00–11:00 PM
Friday, June 26, 2026
Departure
12:00–11:59 PM
Subscribe for Updates